← Home

AYA

Healthcare & BiotechCOILED

$5.620

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted
NIBInvestment banks+$10.8M
RetailRetail · context+$3.5M
WAWealth & advisers+$2.6M
MMMarket makers+$2.2M
ResResource specialists+$1.1M

5d return

+7.2%

20d return

+5.6%

60d return

+38.4%

RSI 14

40.3

vs 52w high

-10.4%

vs 52w low

+473.5%

SMA 20

Below

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.
Loading chart…
Closest correlates
Pearson r on log returns, window: 42d
  • WC8r=0.65, window: 42d
  • AISr=0.64, window: 42d
  • ARUr=0.61, window: 42d
  • TM1r=0.60, window: 42d
  • ATVr=0.59, window: 42d
Announcements — last 30 days
  • 2026-07-23PSotherNortheast Georgia Health System goes live with Salix

    Salix® has achieved first revenue-generating deployment at Northeast Georgia Health System, marking the transition from pilot to commercial operation with dual revenue models (subscription + per-scan). Second U.S. customer now generating revenue; third expected imminently, validating the commercial pathway for this AI-powered coronary disease diagnostic platform.

  • 2026-06-30PSsubstantial_holderBecoming a substantial holder

    UBS Group AG has crossed the 5% substantial holder threshold in Artrya Limited, primarily through prime brokerage arrangements and asset management fund positions accumulated over March–June 2026. This represents institutional confidence in the healthcare AI/imaging software company, though the structure (borrowing rights, stock lending) suggests positions held for clients rather than a strategic long-term commitment.